Evidence map›Paper›PMID 39867713›Full record

ArticleHealth science reports2025

The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial.

Mehrab Sayadi, Sara Javadpour Nowbandegani, Fatemeh Balaghi Inalou, Bahman Nazemzadegan, Shirzad Javidi Alsaadi, Mohammadreza Eskandari, Matin Sepehrinia

Abstract read
In one paragraph

Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Assessment of Zinc Content in Food Supplements.Foods (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mehrab SayadiCardiovascular Research Center Shiraz University of Medical Sciences Shiraz Iran.ORCID https://orcid.org/0000-0003-2575-790X
Sara Javadpour NowbandeganiNon-Communicable Diseases Unit, Vice Chancellor of Health Shiraz University of Medical Sciences Shiraz Iran.ORCID https://orcid.org/0000-0003-3836-3344
Fatemeh Balaghi InalouNon-Communicable Diseases Unit, Vice Chancellor of Food and Drug Administration Shiraz University of Medical Sciences Shiraz Iran.
Bahman NazemzadeganNon-Communicable Diseases Unit, Vice Chancellor of Health Shiraz University of Medical Sciences Shiraz Iran.
Shirzad Javidi AlsaadiNon-Communicable Diseases Unit, Vice Chancellor of Health Shiraz University of Medical Sciences Shiraz Iran.
Mohammadreza EskandariDepartment of Pharmacology and Toxicology, School of Pharmacy Zanjan University of Medical Sciences Zanjan Iran.
Matin SepehriniaNoncommunicable Diseases Research Center Fasa University of Medical Sciences Fasa Iran.ORCID 0009-0006-6063-0030

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds and Aims: Type 2 diabetes and its complications are assumed to be major public health problems globally. Zinc is one of the elements that play a part in insulin secretion and signaling. Therefore, this study seeks the answer to the following question: "What are the effects of 220 mg zinc sulfate supplementation on the weight, blood pressure, and glycemic control of patients with Type 2 diabetes?". Methods: In this randomized controlled double-blind trial, 79 patients with Type 2 diabetes were allocated into two groups through permuted block randomization method. The study group received two capsules of 220 mg of zinc sulfate containing 50 mg of zinc, and the control group received two capsules of 220 mg of placebo ingredient per week for 12 weeks. At the start and end of the treatment period, the fasting blood glucose (FBG), glycated hemoglobin (HbA1c), zinc level, weight, waist circumference (WC), and blood pressure were measured. Results: After 12 weeks of follow-up, 72 patients completed the study. There were no significant differences before and after the intervention in the FBG, HbA1c, zinc levels, and WC between the two groups. Intragroup analysis showed that weight and body mass index increased in the intervention group; however, these changes were not significant in comparison to the control group. Also, diastolic blood pressure significantly increased in the control group; however, changes in systolic blood pressure were not significant in both groups. Conclusion: Taking 220 mg of zinc sulfate supplement twice a week did not show significant benefit for weight, blood pressure, and glycemic control in patients with Type 2 diabetes. Trial Registration: This trial was registered on the Iranian Registry of Clinical Trials (IRCT) website with code number 29627 on September 18, 2018.

Indexed as

diabetes mellitustrace elementszinc

Identifiers

PMID39867713
PMCPMC11758093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.